CN116981664A - 作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途 - Google Patents

作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途 Download PDF

Info

Publication number
CN116981664A
CN116981664A CN202280019540.7A CN202280019540A CN116981664A CN 116981664 A CN116981664 A CN 116981664A CN 202280019540 A CN202280019540 A CN 202280019540A CN 116981664 A CN116981664 A CN 116981664A
Authority
CN
China
Prior art keywords
alkyl
alkylene
heterocycloalkyl
haloalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280019540.7A
Other languages
English (en)
Chinese (zh)
Inventor
R·阿尔-阿瓦尔
L·阿蒂萨诺
M·艾萨克
Y·刘
D·斯米尔
D·尤林
J·弗拉纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontario Cancer Institute
University of Toronto
Mt Sinai Hospital
Original Assignee
Ontario Cancer Institute
University of Toronto
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontario Cancer Institute, University of Toronto, Mt Sinai Hospital filed Critical Ontario Cancer Institute
Publication of CN116981664A publication Critical patent/CN116981664A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280019540.7A 2021-01-07 2022-01-07 作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途 Pending CN116981664A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134739P 2021-01-07 2021-01-07
US63/134,739 2021-01-07
PCT/CA2022/050014 WO2022147620A1 (en) 2021-01-07 2022-01-07 Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Publications (1)

Publication Number Publication Date
CN116981664A true CN116981664A (zh) 2023-10-31

Family

ID=82356983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280019540.7A Pending CN116981664A (zh) 2021-01-07 2022-01-07 作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途

Country Status (7)

Country Link
US (1) US20240025887A1 (https=)
EP (1) EP4274829A4 (https=)
JP (1) JP2024502174A (https=)
CN (1) CN116981664A (https=)
AU (1) AU2022205713A1 (https=)
CA (1) CA3204383A1 (https=)
WO (1) WO2022147620A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116903591B (zh) * 2023-07-13 2025-08-26 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN116903592B (zh) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
CN116947764B9 (zh) * 2023-07-13 2025-07-25 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035891A1 (en) * 2004-05-18 2006-02-16 Hui Li Cycloalkyl substituted pyrimidinediamine compounds and their uses
CN101535276A (zh) * 2006-10-23 2009-09-16 赛福伦公司 作为ALK和c-MET抑制剂的2，4-二氨基嘧啶稠合双环衍生物
US20090306067A1 (en) * 2006-04-10 2009-12-10 Harald Engelhardt 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer
US20100144706A1 (en) * 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
CN110724137A (zh) * 2019-11-13 2020-01-24 广东工业大学 一种噻吩类衍生物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
CA2634646C (en) * 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EA017252B1 (ru) * 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
MX353308B (es) * 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035891A1 (en) * 2004-05-18 2006-02-16 Hui Li Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20090306067A1 (en) * 2006-04-10 2009-12-10 Harald Engelhardt 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer
CN101535276A (zh) * 2006-10-23 2009-09-16 赛福伦公司 作为ALK和c-MET抑制剂的2，4-二氨基嘧啶稠合双环衍生物
US20100144706A1 (en) * 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
CN110724137A (zh) * 2019-11-13 2020-01-24 广东工业大学 一种噻吩类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
JP2024502174A (ja) 2024-01-17
WO2022147620A1 (en) 2022-07-14
EP4274829A1 (en) 2023-11-15
US20240025887A1 (en) 2024-01-25
AU2022205713A9 (en) 2025-03-06
AU2022205713A1 (en) 2023-07-27
CA3204383A1 (en) 2022-07-14
EP4274829A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
CN116940565A (zh) 作为nuak激酶的抑制剂的异吲哚啉酮氨基嘧啶化合物、其组合物和用途
JP6309057B2 (ja) ヒドラジド含有核輸送調節因子およびその使用
CN104854101B (zh) Alk激酶抑制剂
CN116981664A (zh) 作为nuak激酶的抑制剂的噻吩基和环烷基氨基嘧啶化合物、其组合物和用途
TWI438193B (zh) 醯基硫脲化合物或其鹽、及其用途
WO2020224607A1 (zh) Ezh2抑制剂及其用途
US11192880B2 (en) Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders
KR101335746B1 (ko) 이치환된 프탈라진 헷지호그 경로 길항제
CN112778275A (zh) 金刚烷基prmt5抑制剂及其应用
KR20040062591A (ko) 인돌리논 화합물에 의한 급성 골수성 백혈병의 치료방법
EP3679031A1 (en) Inhibitors of wdr5 protein-protein binding
EA019685B1 (ru) Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
WO2014040549A1 (zh) 炔杂芳环化合物及其应用
KR20170054413A (ko) 신규한 화합물
WO2020125759A1 (zh) 作为wnt信号通路抑制剂的化合物及其医学应用
WO2019119144A1 (en) Novel deuterated compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
CN112538083A (zh) 一类靶向bcl6的芳香环并五元芳杂环类小分子有机化合物及其衍生物及其应用
CN113278023B (zh) 含氮杂环化合物及其制备方法和应用
CA3086362C (en) Quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination